Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinations.

Research square·2026
Same author

Deciphering small sequence differences in T cell receptor-antigen pairing.

Nature communications·2026
Same author

Intratumoral TLR4 agonist therapy elicits antigen-specific T cell clonal expansion in metastatic leiomyosarcoma: a case series.

Frontiers in oncology·2026
Same author

Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 Trial.

JCO oncology advances·2026
Same author

Voluntarily Stopping Eating and Drinking (VSED) With Hospice Support in America: A Case Series.

Journal of pain and symptom management·2026
Same author

Implementation of Structured Oncologist Communication Skills Training within the Improving Goal Concordant Care Initiative: Lessons Learned and Future Progress.

Journal of palliative medicine·2026
Same journal

Oral Etoposide for Relapsed or Refractory Ewing Sarcoma in Adolescent and Adult Patients.

Sarcoma·2024
Same journal

Incidence of Undifferentiated Pleomorphic Sarcoma (UPS) in the United States.

Sarcoma·2024
Same journal

Desmoplastic Small Round Cell Tumors: Clinical Presentation, Molecular Characterization, and Therapeutic Approach of Seven Patients.

Sarcoma·2024
Same journal

ATRX and Its Prognostic Significance in Soft Tissue Sarcoma.

Sarcoma·2024
Same journal

Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum.

Sarcoma·2024
Same journal

Exploring the Diagnostic Dilemma of Indeterminate Pulmonary Nodules in Patients with Primary Sarcoma of Bone.

Sarcoma·2024
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Immune-based therapies for sarcoma.

Seth M Pollack1, Elizabeth T Loggers, Eve T Rodler

  • 1Fred Hutchinson Cancer Research Center, University of Washington, 825 Eastlake Avenue East, G3630, Seattle, WA 98109-1023, USA.

Sarcoma
|February 19, 2011
PubMed
Summary
This summary is machine-generated.

Immunotherapy shows promise for sarcoma treatment. Cancer testis antigens offer potential targets for new immunotherapeutic strategies against advanced bone and soft tissue sarcomas.

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Related Experiment Videos

Last Updated: Jun 4, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Immunotherapy has demonstrated efficacy in various cancers, yet its role in sarcoma treatment is still under investigation.
  • Advanced bone and soft tissue sarcomas represent challenging clinical entities with a significant need for novel systemic therapies.
  • Existing research suggests potential benefits of immune-based treatments for sarcomas, but these are not yet standard care.

Purpose of the Study:

  • To review recent advancements in understanding cancer testis antigens within sarcoma.
  • To explore the potential of cancer testis antigens as targets for immunotherapy in sarcoma.
  • To summarize clinical data regarding immunotherapeutic approaches in sarcoma.

Main Methods:

  • Literature review of recent research on cancer testis antigens in sarcoma.
  • Analysis of studies investigating immunotherapeutic strategies for sarcoma.
  • Synthesis of clinical trial data related to immunotherapy for sarcoma subtypes.

Main Results:

  • Several sarcoma subtypes express cancer testis antigens, indicating their potential as immunotherapeutic targets.
  • Emerging clinical data suggests that immunotherapy may offer a viable treatment option for advanced sarcomas.
  • Further research is needed to fully define the role and optimize the application of immunotherapy in sarcoma management.

Conclusions:

  • Cancer testis antigens represent promising targets for developing novel immunotherapies for sarcoma.
  • Immunotherapy holds potential for improving outcomes in patients with advanced bone and soft tissue sarcomas.
  • Continued investigation into sarcoma immunology and clinical trials is crucial for advancing treatment paradigms.